Urogen Pharma (URGN) AI Stock Analysis

• Market Cap: $899.84M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: 10.85%
• EPS Growth: -1.41%
• Country: US
• Employees: 234
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -1.05
• Shares Outstanding: 46,264,133
• 10 Day Avg. Volume: 950,896
• 30 Day Avg. Volume: 1,200,211
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 6.62
• Enterprise Value/Gross Profit: 7.47
• Enterprise Value/Ebitda: -5.30
• 1Y Price Target: $32.75
• Price Target Upside: 68.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 54 Neutral
• Price Target: $18.00 ▼(-7.46% Downside)

Urogen Pharma's stock score is primarily impacted by weak financial performance due to profitability and cash flow challenges. Positive technical indicators and corporate events provide some support, but valuation concerns and earnings call challenges limit the overall score.

Positive Factors

Clinical Data

ZUSDURI long-term clinical data appear compelling with a 78% complete response for patients at three months, and 79% of those patients remained event-free 12 months later.

Market Potential

ZUSDURI could reach blockbuster status given the much larger size of the NMIBC target market and the fact that ZUSDURI is currently the only pharmacotherapy approved to treat recurrent LG-IR-NMIBC.

Product Approval

ZUSDURI has been designed for potent tumor ablation, offering a new alternative for recurrent LG-IR-NMIBC patients who often endure multiple resections under general anesthesia.

Negative Factors

Financial Performance

Revenue and earnings miss moderately—lowering price target based on revised sales ramp trajectory.

Urogen Pharma Business Overview & Revenue Model

Company Description

Urogen Pharma Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases. The company specializes in the research and development of products designed to treat conditions such as bladder cancer and other urological disorders, leveraging its proprietary technology platforms to create targeted therapies. Urogen's core products include its lead investigational therapies, which aim to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions.

How the Company Makes Money

Urogen Pharma generates revenue primarily through the commercialization of its pharmaceutical products. The company earns money by selling its approved therapies to healthcare providers, hospitals, and specialty pharmacies. Key revenue streams include product sales from its marketed therapies and potential royalties from partnerships or licensing agreements related to its drug development programs. Urogen may also engage in collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving certain development goals, and royalties on future sales. Additionally, the company may receive funding through grants or research partnerships that support its clinical trials and development efforts.

Urogen Pharma Financial Statement Overview

Summary

Urogen Pharma shows strong revenue growth, but significant profitability and cash flow challenges persist, coupled with a weak balance sheet marked by negative equity.

Income Statement

Urogen Pharma has demonstrated strong revenue growth, with Total Revenue increasing from $11.8M in 2020 to $91.9M in TTM 2025, a substantial positive trajectory. However, the company is currently unprofitable, with a net loss of $138.4M in TTM 2025. Gross Profit Margin is high at 89.7% for TTM 2025, indicating effective cost management relative to revenue. The EBIT and EBITDA margins are negative, reflecting significant operational challenges.

Balance Sheet

The balance sheet shows a negative Stockholders' Equity of $-46.5M in TTM 2025, raising concerns about financial stability. The Debt-to-Equity ratio is not calculable due to negative equity, indicating potential financial risk. Total Debt is $124.9M, which is high relative to the negative equity. The Equity Ratio is negative, highlighting balance sheet weaknesses.

Cash Flow

Operating cash flow is negative at $-107.1M in TTM 2025, indicating challenges in generating cash from core operations. Free Cash Flow is also negative, suggesting additional pressure on financial resources. However, the financing activities have provided significant cash inflow, helping to mitigate these cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	94.24M	90.40M	82.71M	64.36M	48.04M	11.80M
Gross Profit	83.43M	81.52M	73.35M	56.70M	42.88M	10.79M
EBITDA	-117.64M	-110.33M	-60.35M	-76.21M	-90.15M	-122.71M
Net Income	-154.97M	-126.87M	-102.24M	-109.78M	-110.82M	-128.48M
Balance Sheet
Total Assets	208.72M	285.71M	178.31M	136.24M	119.75M	122.00M
Cash, Cash Equivalents and Short-Term Investments	156.95M	236.69M	136.97M	99.96M	89.14M	102.02M
Total Debt	125.92M	123.39M	100.21M	100.06M	398.00K	1.50M
Total Liabilities	302.09M	294.51M	243.52M	224.98M	111.33M	25.65M
Stockholders Equity	-93.38M	-8.80M	-65.21M	-89.36M	8.41M	96.36M
Cash Flow
Free Cash Flow	-123.53M	-97.06M	-76.57M	-87.81M	-85.64M	-107.10M
Operating Cash Flow	-123.13M	-96.77M	-76.38M	-87.56M	-84.89M	-105.89M
Investing Cash Flow	-43.69M	-20.61M	-953.00K	1.06M	4.07M	93.24M
Financing Cash Flow	40.01M	194.62M	116.93M	97.13M	72.32M	16.53M

Urogen Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For URGN, the sentiment is Positive. The current price of 19.45 is above the 20-day moving average (MA) of 19.37, above the 50-day MA of 17.01, and above the 200-day MA of 11.98, indicating a bullish trend. The MACD of 0.66 indicates Positive momentum. The RSI at 56.58 is Neutral, neither overbought nor oversold. The STOCH value of 55.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for URGN.

Urogen Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	76 Outperform	$789.55M	46.11	37.36%	―	35.89%	―
URGN	54 Neutral	$899.84M	―	-452.20%	―	10.85%	-1.41%
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
ARVN	50 Neutral	$567.52M	―	-35.41%	―	―	―
SVRA	46 Neutral	$566.91M	―	-99.30%	―	―	-21.05%
BCYC	45 Neutral	$511.09M	―	-31.58%	―	-51.13%	7.57%
OPT	39 Underperform	$483.17M	―		―	-80.09%	60.25%

Urogen Pharma Corporate Events

UroGen Pharma Shareholders Approve Key Proposals at Meeting

UroGen Pharma’s shareholders convened at the Annual Meeting to vote on several key proposals. The shareholders elected seven directors, approved an amended compensation policy, and endorsed the 2017 Amended Plan. Additionally, they approved the executive compensation and decided to hold annual advisory votes on this matter. PricewaterhouseCoopers LLP was appointed as the independent auditor until 2026.

UroGen Pharma Approves Bonuses After FDA Approval

On June 30, 2025, UroGen Pharma’s Board of Directors approved special bonuses for key executives, recognizing their leadership in achieving FDA approval for ZUSDURI, a treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer. This approval marks a significant milestone for the company, potentially enhancing its market position and benefiting stakeholders by expanding its therapeutic offerings.

FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer

On June 12, 2025, the FDA approved Urogen Pharma‘s ZUSDURI™, a sustained-release gel formulation of mitomycin, for treating adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This approval is based on the Phase 3 ENVISION trial, where 78% of patients achieved complete response at three months, with 79% maintaining it at 12 months. ZUSDURI is expected to be available in the U.S. by July 1, 2025, and Urogen Pharma has committed to further trials and updates to the FDA to assess long-term benefits.